We are pleased to invite investors and analysts to participate in our virtual event on Monday, 23 June 2025, to highlight new results from Roche’s Hematology pipeline including Phase III (STARGLO) Columvi in R/R DLBCL 2-year data , first presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from 30 May-3 June, 2025, Phase III (SUNMO) data for Lunsumio + Polivy in R/R DLBCL primary analysis, accepted as a late breaking abstract at the International Conference on Malignant Lymphoma (ICML) from 17-21 June 2025, Phase III (POLARGO) data for Polivy in R/R DLBCL selected for Plenary presentation at both the European Hematology Association (EHA) Congress from 12-15 June 2025 and ICML as well as Phase I/II (NXTAGE) data for NXT007 in Hemophilia A presented at the Congress of the International Society on Thrombosis and Haemostasis (ISTH) from 21-25 June 2025.   19:00 - 20:15 CEST / 18:00 - 19:15 BST 1:00 - 2:15 pm EDT / 10:00 - 11:15 am PDT   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 18:00 CEST on the day of the event. > click here Agenda Introduction Bruno Eschli, Head of Investor Relations Malignant Hematology Franchise Update Charles Fuchs, SVP Global Head of Oncology and Hematology, Product Development NHL: FL update; DLBCL: Lunsumio+Polivy - Ph III (SUNMO) Primary Analysis; Columvi - Ph III (STARGLO) 2y data Charles Fuchs, SVP Global Head of Oncology and Hematology, Product Development Non-Malignant Hematology Franchise Update Daud Chaudry, Lifecycle Leader Hemophilia Bispecifics, Global Product Strategy Hemophilia: NXT007 - Ph I/II (NXTAGE) Primary Analysis Daud Chaudry, Lifecycle Leader Hemophilia Bispecifics, Global Product Strategy Q&A   Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > roche.com/investors   *privacy notice   Best regards,
Bruno Eschli Head of Investor Relations	Rishard Salie Investor Relations Officer	Jan-Philipp Schwarzhans Investor Relations Officer

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

get the latest news and updates to your inbox.